-
1
-
-
0035857351
-
Osteoporosis prevention, diagnosis, and therapy
-
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285: 785-795.
-
(2001)
JAMA
, vol.285
, pp. 785-795
-
-
-
2
-
-
0030704306
-
Prevalence of low femoral bone density in older US adults from NHANES III
-
Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1761-1768
-
-
Looker, A.C.1
Orwoll, E.S.2
Johnston Jr., C.C.3
-
3
-
-
0036321486
-
Osteoporosis in men
-
Binkley N, Krueger D. Osteoporosis in men. WMJ. 2002;101:28-32.
-
(2002)
WMJ
, vol.101
, pp. 28-32
-
-
Binkley, N.1
Krueger, D.2
-
4
-
-
0031036671
-
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
-
Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 24-35
-
-
Ray, N.F.1
Chan, J.K.2
Thamer, M.3
-
6
-
-
0037120864
-
Clinical use of bone densitometry: Scientific review
-
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897.
-
(2002)
JAMA
, vol.288
, pp. 1889-1897
-
-
Cummings, S.R.1
Bates, D.2
Black, D.M.3
-
7
-
-
0034900335
-
American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
-
Osteoporosis Task Force. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:293-312.
-
(2001)
Endocr Pract
, vol.7
, pp. 293-312
-
-
-
9
-
-
0037125848
-
Screening for osteoporosis in postmenopausal women: Recommendations and rationale
-
US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137: 526-528.
-
(2002)
Ann Intern Med
, vol.137
, pp. 526-528
-
-
-
10
-
-
0032869574
-
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis
-
Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10:259-264.
-
(1999)
Osteoporos Int
, vol.10
, pp. 259-264
-
-
Genant, H.K.1
Cooper, C.2
Poor, G.3
-
11
-
-
0036402485
-
What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians?
-
Binkley N, Schemeer P, Wasnich R, et al. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom. 2002;5(suppl):S19-S27.
-
(2002)
J Clin Densitom
, vol.5
, Issue.SUPPL.
-
-
Binkley, N.1
Schemeer, P.2
Wasnich, R.3
-
12
-
-
0029742361
-
Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments
-
Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int. 1996;6:265-275.
-
(1996)
Osteoporos Int
, vol.6
, pp. 265-275
-
-
Ankjaer-Jensen, A.1
Johnell, O.2
-
13
-
-
0036234263
-
Secondary causes of osteoporosis
-
Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77: 453-468.
-
(2002)
Mayo Clin Proc
, vol.77
, pp. 453-468
-
-
Fitzpatrick, L.A.1
-
14
-
-
0036776241
-
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women
-
Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431-4437.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 4431-4437
-
-
Tannenbaum, C.1
Clark, J.2
Schwartzman, K.3
-
15
-
-
0026613738
-
Vitamin D3 and calcium to prevent hip fractures in the elderly women
-
Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637-1642.
-
(1992)
N Engl J Med
, vol.327
, pp. 1637-1642
-
-
Chapuy, M.C.1
Arlot, M.E.2
Duboeuf, F.3
-
16
-
-
0028295830
-
Effect of calcium and cholecaldiferal treatment for 3 years on hip fractures in elderly women
-
Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecaldiferal treatment for 3 years on hip fractures in elderly women. BMJ. 1994;308:1081-1082.
-
(1994)
BMJ
, vol.308
, pp. 1081-1082
-
-
Chapuy, M.C.1
Arlot, M.E.2
Delmas, P.D.3
-
17
-
-
0028949069
-
Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
-
Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995;98:331-335.
-
(1995)
Am J Med
, vol.98
, pp. 331-335
-
-
Reid, I.R.1
Ames, R.W.2
Evans, M.C.3
-
18
-
-
0030449017
-
Correcting calcium nutritional deficiency prevents spine fractures in elderly women
-
Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res. 1996;11: 1961-1966.
-
(1996)
J Bone Miner Res
, vol.11
, pp. 1961-1966
-
-
Recker, R.R.1
Hinders, S.2
Davies, K.M.3
-
19
-
-
0030763532
-
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
-
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
-
(1997)
N Engl J Med
, vol.337
, pp. 670-676
-
-
Dawson-Hughes, B.1
Harris, S.S.2
Krall, E.A.3
-
21
-
-
0032524767
-
Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture: A randomized, double-blind, placebo-controlled trial
-
Schurch MA, Rizzoli R, Slosman D, et al. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:801-809.
-
(1998)
Ann Intern Med
, vol.128
, pp. 801-809
-
-
Schurch, M.A.1
Rizzoli, R.2
Slosman, D.3
-
22
-
-
0031817494
-
Physical activity and osteoporotic fracture risk in older women
-
Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Ann Intern Med. 1998;129:81-88.
-
(1998)
Ann Intern Med
, vol.129
, pp. 81-88
-
-
Gregg, E.W.1
Cauley, J.A.2
Seeley, D.G.3
-
23
-
-
0036048481
-
Exercise for preventing and treating osteoporosis in postmenopausal women
-
CD000333
-
Bonaiuti D, Shea, B, Iovine, R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2002;3: CD000333.
-
(2002)
Cochrane Database Syst Rev
, vol.3
-
-
Bonaiuti, D.1
Shea, B.2
Iovine, R.3
-
24
-
-
0037073281
-
Walking and leisure-time activity and risk of hip fracture in postmenopausal women
-
Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA. 2002;288:2300-2306.
-
(2002)
JAMA
, vol.288
, pp. 2300-2306
-
-
Feskanich, D.1
Willett, W.2
Colditz, G.3
-
25
-
-
0028596397
-
Effects of high-intensity strength training on multiple risk factors of osteoporotic fractures
-
Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors of osteoporotic fractures. JAMA. 1994;272: 1909-1914.
-
(1994)
JAMA
, vol.272
, pp. 1909-1914
-
-
Nelson, M.E.1
Fiatarone, M.A.2
Morganti, C.M.3
-
26
-
-
0028014350
-
The bone density of female twins discordant for tobacco use
-
Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med. 1994;330:387-392.
-
(1994)
N Engl J Med
, vol.330
, pp. 387-392
-
-
Hopper, J.L.1
Seeman, E.2
-
27
-
-
0027055405
-
Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women
-
Kiel DP, Baron JA, Anderson JJ, et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med. 1992;116:716-721.
-
(1992)
Ann Intern Med
, vol.116
, pp. 716-721
-
-
Kiel, D.P.1
Baron, J.A.2
Anderson, J.J.3
-
28
-
-
0343570526
-
Identification of early postmenopausal women with no bone response to HRT: Results of a 5-year clinical trial
-
Komulainen M, Kroger H, Tuppurainen MT, et al. Identification of early postmenopausal women with no bone response to HRT: results of a 5-year clinical trial. Osteoporos Int. 2000;11:211-218.
-
(2000)
Osteoporos Int
, vol.11
, pp. 211-218
-
-
Komulainen, M.1
Kroger, H.2
Tuppurainen, M.T.3
-
30
-
-
0028860231
-
Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women
-
Cauley JA, Seeley DG, Ensrud K, et al, Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995; 122:9-16.
-
(1995)
Ann Intern Med
, vol.122
, pp. 9-16
-
-
Cauley, J.A.1
Seeley, D.G.2
Ensrud, K.3
-
31
-
-
0026691295
-
Treatment of postmenopausal osteoporosis with transdermal estrogen
-
Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
-
(1992)
Ann Intern Med
, vol.117
, pp. 1-9
-
-
Lufkin, E.G.1
Wahner, H.W.2
O'Fallon, W.M.3
-
32
-
-
0029907556
-
Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
-
Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
-
(1996)
JAMA
, vol.276
, pp. 1389-1396
-
-
-
33
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
34
-
-
0032547326
-
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
-
Hulley S, Grady D, Bush T, et al, Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
-
(1998)
JAMA
, vol.280
, pp. 605-613
-
-
Hulley, S.1
Grady, D.2
Bush, T.3
-
35
-
-
0033675229
-
Focus on primary care postmenopausal osteoporosis: An update
-
Watts NB. Focus on primary care postmenopausal osteoporosis: an update. Obstet Gynecol Surv. 2000;55:S49-S55.
-
(2000)
Obstet Gynecol Surv
, vol.55
-
-
Watts, N.B.1
-
36
-
-
0026671983
-
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
-
Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-561.
-
(1992)
BMJ
, vol.305
, pp. 556-561
-
-
Overgaard, K.1
Hansen, M.A.2
Jensen, S.B.3
-
37
-
-
0027931018
-
A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
-
Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest. 1994;24:565-569.
-
(1994)
Eur J Clin Invest
, vol.24
, pp. 565-569
-
-
Reginster, J.Y.1
Meurmans, L.2
Deroisy, R.3
-
38
-
-
0028914618
-
Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
-
Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int. 1995;56:181-185.
-
(1995)
Calcif Tissue Int
, vol.56
, pp. 181-185
-
-
Rico, H.1
Revilla, M.2
Hernandez, E.R.3
-
39
-
-
0033829969
-
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study
-
Chestnut CH III, Silverman S, Andriano K, et al, PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med. 2000;109:267-276.
-
(2000)
Am J Med
, vol.109
, pp. 267-276
-
-
Chestnut III, C.H.1
Silverman, S.2
Andriano, K.3
-
40
-
-
0036185685
-
Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint
-
Marcus R, Wong M, Heath H III, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002;23:16-37.
-
(2002)
Endocr Rev
, vol.23
, pp. 16-37
-
-
Marcus, R.1
Wong, M.2
Heath III, H.3
Stock, J.L.4
-
41
-
-
0026335249
-
Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study
-
Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calci. tonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int. 1991;49:369-372.
-
(1991)
Calcif Tissue Int
, vol.49
, pp. 369-372
-
-
Lyritis, G.P.1
Tsakalakos, N.2
Magiasis, B.3
-
42
-
-
0033431687
-
Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: A prospective double-blind, randomized, placebo-controlled clinical study
-
Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999;15:284-289.
-
(1999)
Clin J Pain
, vol.15
, pp. 284-289
-
-
Lyritis, G.P.1
Ioannidis, G.V.2
Karachalios, T.3
-
43
-
-
0026010523
-
Use of calcitonin in the treatment of bone pain associated with osteoporosis
-
Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int. 1991;49(suppl 2):S9-S13.
-
(1991)
Calcif Tissue Int
, vol.49
, Issue.SUPPL. 2
-
-
Gennari, C.1
Agnusdei, D.2
Camporeale, A.3
-
44
-
-
0035081522
-
Treatment of osteoporosis with bisphosphonates
-
Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001;27:197-214.
-
(2001)
Rheum Dis Clin North Am
, vol.27
, pp. 197-214
-
-
Watts, N.B.1
-
45
-
-
0028851590
-
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
-
Liberman UA, Weiss SR, Broll J, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-1443.
-
(1995)
N Engl J Med
, vol.333
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Broll, J.3
-
46
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
-
Black DM, Cummings SR, Karpf DB, et al, Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
47
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
48
-
-
0032896590
-
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
-
Pols HA, Felsenberg D, Hanley DA, et al, Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9;461-468.
-
(1999)
Osteoporos Int
, vol.9
, pp. 461-468
-
-
Pols, H.A.1
Felsenberg, D.2
Hanley, D.A.3
-
49
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
-
Harris ST, Watts NB, Genant HK, et al, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
50
-
-
0035253489
-
Effect of risedronate on the risk of hip fracture in elderly women
-
McClung M, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
-
(2001)
N Engl J Med
, vol.344
, pp. 333-340
-
-
McClung, M.1
Geusens, P.2
Miller, P.D.3
-
51
-
-
0036789682
-
Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence?
-
Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-1043.
-
(2002)
Mayo Clin Proc
, vol.77
, pp. 1031-1043
-
-
Cryer, R.1
Bauer, D.C.2
-
52
-
-
0034097152
-
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
-
Schnitzer T, Bone HG, Crepaldi G, et al, Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis, Aging. 2000;12:1.12.
-
(2000)
Aging
, vol.12
-
-
Schnitzer, T.1
Bone, H.G.2
Crepaldi, G.3
-
53
-
-
0037365262
-
Bone density changes with once weekly risedronate in postmenopausal women
-
Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom. 2003;6:45-50.
-
(2003)
J Clin Densitom
, vol.6
, pp. 45-50
-
-
Delaney, M.F.1
Hurwitz, S.2
Shaw, J.3
LeBoff, M.S.4
-
54
-
-
0036112229
-
Response of bone mineral density to once-weekly administration of risedronate
-
Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract. 2002;8:202-207.
-
(2002)
Endocr Pract
, vol.8
, pp. 202-207
-
-
Gordon, M.S.1
Gordon, M.B.2
-
55
-
-
0037186928
-
Bisphosphonates and osteoporosis
-
Solomon CG. Bisphosphonates and osteoporosis [comment]. N Engl J Med. 2002;346:642.
-
(2002)
N Engl J Med
, vol.346
, pp. 642
-
-
Solomon, C.G.1
-
56
-
-
0037186926
-
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
-
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346: 653-661.
-
(2002)
N Engl J Med
, vol.346
, pp. 653-661
-
-
Reid, I.R.1
Brown, J.P.2
Burckhardt, P.3
-
57
-
-
0036679350
-
Meta-analyses of therapies for postmenopausal osteoporosis, IV: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis
-
Cranney A, Tugwell P, Zytaruk N, et al, Osteoporosis Methodology Group and Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis, IV: meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524-528.
-
(2002)
Endocr Rev
, vol.23
, pp. 524-528
-
-
Cranney, A.1
Tugwell, P.2
Zytaruk, N.3
-
58
-
-
0033581212
-
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
-
Ettinger B, Black DM, Mitlak BH, et al, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
-
(1999)
JAMA
, vol.282
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
-
59
-
-
0034455674
-
Comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
-
Prestwood KM, Gunness M, Muchmore DB, et al. Comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 2197-2202
-
-
Prestwood, K.M.1
Gunness, M.2
Muchmore, D.B.3
-
60
-
-
0036963450
-
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
-
Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87: 985-992.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 985-992
-
-
Johnell, O.1
Scheele, W.H.2
Lu, Y.3
-
61
-
-
0030664688
-
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
-
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
-
(1997)
N Engl J Med
, vol.337
, pp. 1641-1647
-
-
Delmas, P.D.1
Bjarnason, N.H.2
Mitlak, B.H.3
-
62
-
-
0034931645
-
From adjuvant therapy to breast cancer prevention: BCPT and STAR
-
Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J. 2001;7:144-157.
-
(2001)
Breast J
, vol.7
, pp. 144-157
-
-
Dunn, B.K.1
Ford, L.G.2
-
63
-
-
0035880662
-
Design and methods of the Raloxifene Use for the Heart (RUTH) study
-
Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol. 2001;88:392-395.
-
(2001)
Am J Cardiol
, vol.88
, pp. 392-395
-
-
Mosca, L.1
Barrett-Connor, E.2
Wenger, N.K.3
-
65
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
-
(2001)
N Engl J Med
, vol.344
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
-
66
-
-
18644374464
-
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
-
Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 4528-4535
-
-
Body, J.J.1
Gaich, G.A.2
Scheele, W.H.3
-
67
-
-
3242748818
-
-
RPhLink.com. Forteo. Available at: http://www.rphlink.com/forteo.html. Accessed August 24, 2003.
-
Forteo
-
-
-
68
-
-
0037436821
-
Phytoestrogens: Endocrine disrupters or replacement for hormone replacement therapy?
-
Wuttke W, Jarry H, Becker T, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas. 2003;44:S9-S20.
-
(2003)
Maturitas
, vol.44
-
-
Wuttke, W.1
Jarry, H.2
Becker, T.3
-
69
-
-
0027177212
-
Hip fracture rates in Hong Kong and the United States, 1988-1989
-
Ho SC, Bacon WE, Harris T, et al. Hip fracture rates in Hong Kong and the United States, 1988-1989. Am J Public Health. 1993;83:694-697.
-
(1993)
Am J Public Health
, vol.83
, pp. 694-697
-
-
Ho, S.C.1
Bacon, W.E.2
Harris, T.3
-
70
-
-
0032116898
-
Clinical Review 97: Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence
-
Tham DM, Gardner CCD, Haskell WL. Clinical Review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998;83:2223-2225.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 2223-2225
-
-
Tham, D.M.1
Gardner, C.C.D.2
Haskell, W.L.3
-
71
-
-
2042430910
-
Iprioflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women
-
Alexanderson P, Toussaint A, Reginster J. Iprioflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women [abstract]. J Bone Miner Res. 2000;15:S198.
-
(2000)
J Bone Miner Res
, vol.15
-
-
Alexanderson, P.1
Toussaint, A.2
Reginster, J.3
-
72
-
-
0028137814
-
Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate
-
Erdtsieck RJ, Van Kujik C, Birkenhager-Frenkel DH, et al. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res. 1994;9:277-283.
-
(1994)
J Bone Miner Res
, vol.9
, pp. 277-283
-
-
Erdtsieck, R.J.1
Van Kujik, C.2
Birkenhager-Frenkel, D.H.3
-
73
-
-
0033973263
-
Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
-
Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 2000;34:161-168.
-
(2000)
Maturitas
, vol.34
, pp. 161-168
-
-
Castelo-Branco, C.1
Vicente, J.J.2
Figueras, F.3
-
74
-
-
0029057967
-
Growth hormone deficiency in adults and its response to growth hormone replacement
-
Labram EK, Wilkin TJ. Growth hormone deficiency in adults and its response to growth hormone replacement. QJM. 1995;88:391-399.
-
(1995)
QJM
, vol.88
, pp. 391-399
-
-
Labram, E.K.1
Wilkin, T.J.2
-
75
-
-
0016776460
-
On an attempt to treat primary and secondary osteoporosis with human growth hormone
-
Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res. 1975;7:488-491.
-
(1975)
Horm Metab Res
, vol.7
, pp. 488-491
-
-
Kruse, H.P.1
Kuhlencordt, F.2
-
77
-
-
0030906085
-
Skeletal effects of cyclic recombinant growth hormone and salmon calcitonin in osteopenic postmenopausal women
-
Holloway L, Kohlmeier L, Kent K, et al. Skeletal effects of cyclic recombinant growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab. 1997;82:1111-1117.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 1111-1117
-
-
Holloway, L.1
Kohlmeier, L.2
Kent, K.3
-
78
-
-
0032452531
-
Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study
-
Langlois JA, Rosen CJ, Visser M, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab. 1998;83:4257-4262.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 4257-4262
-
-
Langlois, J.A.1
Rosen, C.J.2
Visser, M.3
-
79
-
-
17744389368
-
One year of insulin-like growth factor I treatment does not affect bone density, body composition or psychological measures in postmenopausal women
-
Friedlander AL, Butterfield GE, Moynihan S, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 2001;86:1496-1503.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 1496-1503
-
-
Friedlander, A.L.1
Butterfield, G.E.2
Moynihan, S.3
-
80
-
-
0036205571
-
Potential use of HMG-CoA reductase inhibitors for osteoporosis
-
Cushenberry LM, de Bittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann Pharmacother. 2002;36:671-678.
-
(2002)
Ann Pharmacother
, vol.36
, pp. 671-678
-
-
Cushenberry, L.M.1
De Bittner, M.R.2
-
81
-
-
0035725534
-
Boning up (or down) on statins
-
Demer LL. Boning up (or down) on statins [comment]. Arterioscler Thromb Vasc Biol. 2001;21:1565-1566.
-
(2001)
Arterioscler Thromb Vasc Biol
, vol.21
, pp. 1565-1566
-
-
Demer, L.L.1
-
82
-
-
0036190491
-
Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study
-
Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-540.
-
(2002)
Arch Intern Med
, vol.162
, pp. 537-540
-
-
Pasco, J.A.1
Kotowicz, M.A.2
Henry, M.J.3
-
83
-
-
0035985878
-
Osteoporosis in men: Pathophysiology, evaluation, and therapy
-
Burgess E, Nanes MS. Osteoporosis in men: pathophysiology, evaluation, and therapy. Curr Opin Rheumatol. 2002;14:421-428.
-
(2002)
Curr Opin Rheumatol
, vol.14
, pp. 421-428
-
-
Burgess, E.1
Nanes, M.S.2
-
84
-
-
0030914252
-
Calcaneal bone mineral density predicts fracture occurrence: A five-year follow-up study in elderly people
-
Cheng S, Suominen H, Sakari-Rantala R, Laukkanen P, Avikainen V, Heikkinen E. Calcaneal bone mineral density predicts fracture occurrence: a five-year follow-up study in elderly people. J Bone Miner Res. 1997;12:1075-1082.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1075-1082
-
-
Cheng, S.1
Suominen, H.2
Sakari-Rantala, R.3
Laukkanen, P.4
Avikainen, V.5
Heikkinen, E.6
-
85
-
-
0001013799
-
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
-
Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds [abstract]. J Bone Miner Res. 2001;16:S194.
-
(2001)
J Bone Miner Res
, vol.16
-
-
Kanis, J.A.1
Johnell, O.2
Oden, A.3
-
86
-
-
0033814751
-
Assessing bone density in men
-
Orwoll E. Assessing bone density in men. J Bone Miner Res. 2000;15:1867-1870.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 1867-1870
-
-
Orwoll, E.1
-
87
-
-
0034075945
-
Do men and women fracture bones at similar bone densities?
-
Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int. 2000;11:153-157.
-
(2000)
Osteoporos Int
, vol.11
, pp. 153-157
-
-
Selby, P.L.1
Davies, M.2
Adams, J.E.3
-
88
-
-
0003802711
-
-
Hyattsville, Md: National Center for Health Statistics, Dept of Health and Human Services. CD-ROM Series 11, No. 2A
-
Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey III, 1988-1994. Hyattsville, Md: National Center for Health Statistics, Dept of Health and Human Services. CD-ROM Series 11, No. 2A.
-
National Health and Nutrition Examination Survey III, 1988-1994
-
-
-
89
-
-
0030749167
-
Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture
-
Thiebaud D, Burckhardt P, Cosstanza M, et al. Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporos Int. 1997;7:457-462.
-
(1997)
Osteoporos Int
, vol.7
, pp. 457-462
-
-
Thiebaud, D.1
Burckhardt, P.2
Cosstanza, M.3
-
92
-
-
0034739277
-
Alendronate for the treatment of osteoporosis in men
-
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
-
(2000)
N Engl J Med
, vol.343
, pp. 604-610
-
-
Orwoll, E.1
Ettinger, M.2
Weiss, S.3
-
93
-
-
0035187341
-
Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study
-
Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001;86:5252-5255.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 5252-5255
-
-
Ringe, J.D.1
Faber, H.2
Dorst, A.3
-
94
-
-
0022758151
-
Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
-
Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986;1:377-381.
-
(1986)
J Bone Miner Res
, vol.1
, pp. 377-381
-
-
Slovik, D.M.1
Rosenthal, D.I.2
Doppelt, S.H.3
-
95
-
-
0033710488
-
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
-
Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-3076.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 3069-3076
-
-
Kurland, E.S.1
Cosman, F.2
McMahon, D.J.3
-
96
-
-
0034761548
-
Androgen replacement in aging men
-
Francis RM. Androgen replacement in aging men. Calcif Tissue Int. 2001;69: 235-238.
-
(2001)
Calcif Tissue Int
, vol.69
, pp. 235-238
-
-
Francis, R.M.1
-
97
-
-
0029923842
-
Androgen supplementation in eugonadal men with osteoporosis: Effects of 6 months of treatment on bone mineral density and cardiovascular risk factors
-
Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171-177.
-
(1996)
Bone
, vol.18
, pp. 171-177
-
-
Anderson, F.H.1
Francis, R.M.2
Faulkner, K.3
-
98
-
-
0030899249
-
Androgen supplementation in eugonadal men with osteoporosis: Effects of 6 months' treatment on markers of bone formation and resorption
-
Anderson FH, Francis RM, Peaston RT, et al. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months' treatment on markers of bone formation and resorption. J Bone Miner Res. 1997;12:472-478.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 472-478
-
-
Anderson, F.H.1
Francis, R.M.2
Peaston, R.T.3
-
99
-
-
0030852561
-
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
-
Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82: 2386-2390.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 2386-2390
-
-
Behre, H.M.1
Kliesch, S.2
Leifke, E.3
-
100
-
-
0035925768
-
Treatment of postmenopausal osteoporosis
-
Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001;285:1415-1418.
-
(2001)
JAMA
, vol.285
, pp. 1415-1418
-
-
Altkorn, D.1
Vokes, T.2
-
101
-
-
0036119735
-
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
-
Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
-
(2002)
Am J Med
, vol.112
, pp. 281-289
-
-
Cummings, S.R.1
Karpf, D.B.2
Harris, F.3
-
102
-
-
0000594779
-
Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
-
Emkey R, Reid I, Mulloy A, et al. Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women [abstractl. J Bone Miner Res. 2002;17(suppl 1):S139.
-
(2002)
J Bone Miner Res
, vol.17
, Issue.SUPPL. 1
-
-
Emkey, R.1
Reid, I.2
Mulloy, A.3
-
103
-
-
0032033065
-
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
-
Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998;104:219-226.
-
(1998)
Am J Med
, vol.104
, pp. 219-226
-
-
Wimalawansa, S.J.1
-
104
-
-
17744392399
-
Alendronate and estrogen effects in postmenopausal women with low bone mineral density
-
Bone HG, Greenspan SL, McKeever C, et al, Alendronate/Estrogen Study Group. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Enocrinol Metab. 2000;85:720-726.
-
(2000)
J Clin Enocrinol Metab
, vol.85
, pp. 720-726
-
-
Bone, H.G.1
Greenspan, S.L.2
McKeever, C.3
-
105
-
-
0033304521
-
Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
-
Lindsay R, Cosman F, Lobo TA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, pp. 3076-3081
-
-
Lindsay, R.1
Cosman, F.2
Lobo, T.A.3
-
106
-
-
0036963450
-
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
-
Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87: 985-992.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 985-992
-
-
Johnell, O.1
Scheele, W.H.2
Lu, Y.3
-
107
-
-
0036962096
-
For osteoporosis, are 2 antiresorptive drugs better than one?
-
Ettinger B, Bilezekian JP. For osteoporosis, are 2 antiresorptive drugs better than one? J Clin Endocrinol Metab. 2002;87:983-984.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 983-984
-
-
Ettinger, B.1
Bilezekian, J.P.2
-
108
-
-
0037253242
-
Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures
-
Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21:305-314.
-
(2003)
Pharmacoeconomics
, vol.21
, pp. 305-314
-
-
Johnell, O.1
Jonsson, B.2
Jonsson, L.3
Black, D.4
-
109
-
-
0032726497
-
Current controversies in cost effectiveness analysis of osteoporosis therapies
-
Cranney A, Coyle D, Welch V, et al. Current controversies in cost effectiveness analysis of osteoporosis therapies. J Rheumatol. 1999;26:2300-2302.
-
(1999)
J Rheumatol
, vol.26
, pp. 2300-2302
-
-
Cranney, A.1
Coyle, D.2
Welch, V.3
-
110
-
-
0031791703
-
Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
-
Executive Summary. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8 (suppl 4):S3-S6.
-
(1998)
Osteoporos Int
, vol.8
, Issue.SUPPL. 4
-
-
-
111
-
-
0037369962
-
Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: A review of the literature, 2001-2002
-
Tella MN, Feinglass J, Chang RW. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002. Curr Opin Rheumatol. 2003;15:127-131.
-
(2003)
Curr Opin Rheumatol
, vol.15
, pp. 127-131
-
-
Tella, M.N.1
Feinglass, J.2
Chang, R.W.3
-
112
-
-
0028088849
-
Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly
-
Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. 1994;271: 128-133.
-
(1994)
JAMA
, vol.271
, pp. 128-133
-
-
Greenspan, S.L.1
Myers, E.R.2
Maitland, L.A.3
|